| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNN4 |
| Uniprot No | O15554 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 328-427aa |
| 氨基酸序列 | HTRRKESHAARRHQRKLLAAINAFRQVRLKHRKLREQVNSMVDISKMHMILYDLQQNLSSSHRALEKQIDTLAGKLDALTELLSTALGPRQLPEPSQQSK |
| 预测分子量 | 47,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCNN4重组蛋白的3篇参考文献示例(注：内容为模拟概括，实际文献需根据具体研究确认)：
1. **"Structural insights into KCNN4 channel gating by Ca²⁺ and small molecule modulators"**
*作者：Zhang et al. (2021)*
**摘要**：通过冷冻电镜解析重组人源KCNN4蛋白与钙调蛋白及抑制剂复合物的结构，揭示了Ca²⁺依赖的门控机制及药物结合位点，为靶向治疗提供依据。
2. **"Recombinant KCNN4 expression enhances migration in colorectal cancer cells via MAPK signaling"**
*作者：Lee & Park (2019)*
**摘要**：研究重组KCNN4蛋白在结直肠癌细胞中的过表达效应，发现其通过激活MAPK通路促进细胞迁移，提示KCNN4作为癌症转移的潜在靶点。
3. **"Functional characterization of KCNN4 mutations in hereditary xerocytosis using recombinant channels"**
*作者：Almoguera et al. (2017)*
**摘要**：利用重组KCNN4蛋白模拟遗传性干瘪红细胞增多症相关突变，证实特定突变导致通道活性异常，阐明了红细胞渗透脆性增加的机制。
4. **"High-throughput screening of KCNN4 inhibitors using a fluorescence-based assay with recombinant protein"**
*作者：Smith et al. (2020)*
**摘要**：开发基于重组KCNN4蛋白的荧光筛选平台，鉴定出新型小分子抑制剂，并验证其在自身免疫性疾病模型中的抗炎效果。
(注：以上文献为示例性内容，实际引用需参考真实发表的研究。)
KCNN4. also known as SK4 or KCa3.1. is a potassium calcium-activated channel subfamily N member 4 encoded by the *KCNN4* gene. It belongs to the intermediate-conductance calcium-activated potassium (KCa) channel family, which regulates cellular membrane potential and calcium signaling. This channel is widely expressed in immune cells (e.g., T lymphocytes, macrophages), epithelial cells, endothelial cells, and certain cancer cells, where it plays roles in proliferation, migration, and secretory functions. Its activity is tightly controlled by intracellular calcium levels via calmodulin binding, making it a critical mediator of calcium-dependent cellular responses.
Structurally, KCNN4 comprises six transmembrane domains with intracellular N- and C-termini, forming a tetrameric pore selective for potassium ions. Recombinant KCNN4 proteins are engineered in vitro using expression systems (e.g., HEK293 cells, *E. coli*) to study channel properties, screen modulators, or develop therapeutic agents. These recombinant proteins retain functional features of native channels, enabling researchers to investigate their pharmacological profiles, biophysical characteristics, and disease-related mutations.
Research highlights KCNN4's involvement in pathological conditions, including cancers, inflammatory diseases, and fibrosis. For example, upregulated KCNN4 in solid tumors promotes cancer cell invasion and metastasis, while in autoimmune disorders, it modulates immune cell activation. Inhibitors like TRAM-34 selectively block KCa3.1 channels, showing therapeutic potential in preclinical models of asthma, atherosclerosis, and sickle cell disease. Recombinant KCNN4 also aids in structural studies to design targeted drugs and understand mutation-induced dysfunction. Despite progress, challenges remain in optimizing specificity and delivery of KCNN4-targeted therapies, underscoring the need for further research into its complex regulatory mechanisms.
×
